Peptides / Gut and digestion

Synthetic analog · 33 amino acids

Apraglutide

Not approved

Apraglutide is an experimental long-acting GLP-2 analog in phase 3 trials for short bowel syndrome with intestinal failure and not approved. Studies in people tested it on gut function, nutrient absorption, gut bacteria and IV nutrition needs, and tracked side effects. PepBank shows 58 results on apraglutide from 8 studies in people, and 52 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as FE 203799, FE203799

Evidence level: Large trials in people58 of 110 results come from studies in people, including randomized trials.

Results in people

53% of 110 results

Results in animals

43% of 110 results

Results in lab cells

5% of 110 results

From computer models

0% of 110 results

Overview

Apraglutide at a glance

What it is	Synthetic analog, 33 amino acids
Approval	Not approved for any use
In sport	Status unknown
Studies	16 studies with results. 15 of them gave apraglutide, with 110 results. 58 in people47 in animals5 in lab cells
Best study in people	Randomized controlled trial with 163 people (2026)
Clinical trials	None registered

The science

What is apraglutide?

A long-acting GLP-2 analog studied for short bowel syndrome with intestinal failure.

Amino acids in one chain

Apraglutide structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Structure

Apraglutide is a synthetic analog of 33 amino acids, with no ring, 2 changed amino acids.

CAS number

1295353-98-8

Target

GLP2R (gene GLP2R): agonistEvidence: Primary receptor potency and selectivity experiments establish GLP-2 receptor agonism.

Development

Ironwood Pharmaceuticals. Highest phase: phase 3.

Identifiers

ChEMBL CHEMBL4563522, UNII CVQ1IAY2G6, IUPHAR 10685

See charge, composition and 3D structure on the Scientific page

The evidence

What apraglutide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people58 of 110 results come from studies in people, including randomized trials.

Stomach and gut

56 results · 25 in people · 31 animal

In adults with SBS-IF, apraglutide increased urine output by 714 ml/day more than placebo. JPEN. Journal of parenteral and enteral nutrition, 2022

Top results

In adults with SBS-IF, apraglutide increased urine output by 714 ml/day more than placebo. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In adults with short bowel syndrome, overall gut microbial diversity did not change during apraglutide treatment. (Clinical nutrition ESPEN, 2026)
In adults with short bowel syndrome, stool output decreased during apraglutide treatment. (Clinical nutrition, 2024)

Survival and serious illness

9 results · 7 in people · 2 animal

In people with short bowel syndrome, apraglutide reduced intravenous support volume more than placebo at week 24. Clinical gastroenterology and hepatology, 2026

Top results

In people with short bowel syndrome, apraglutide reduced intravenous support volume more than placebo at week 24. (Clinical gastroenterology and hepatology, 2026)
In mice receiving chemotherapy, apraglutide improved survival versus chemotherapy alone. (Annals of transplantation, 2024)
In adults with short bowel syndrome, intravenous support volume decreased during apraglutide treatment. (Clinical nutrition, 2024)

Weight and appetite

3 results · 3 animal

In piglets with SBS, weight gain was similar with apraglutide and saline on day 7. JPEN. Journal of parenteral and enteral nutrition, 2019

Top results

In piglets with SBS, weight gain was similar with apraglutide and saline on day 7. (JPEN. Journal of parenteral and enteral nutrition, 2019)
In mice receiving chemotherapy, apraglutide reduced weight loss versus chemotherapy alone. (Annals of transplantation, 2024)
In irradiated mice receiving transplantation, apraglutide reduced weight loss versus groups without apraglutide. (Annals of transplantation, 2024)

Immune system and inflammation

1 result · 1 animal

In mice receiving chemotherapy, apraglutide did not affect leukocyte counts versus chemotherapy alone. Annals of transplantation, 2024

Top results

In mice receiving chemotherapy, apraglutide did not affect leukocyte counts versus chemotherapy alone. (Annals of transplantation, 2024)

All 16 apraglutide studies by area Open the Scientific page

Key apraglutide studies

Studies in people come first, then studies in animals and in the lab.

People
STARS Phase 3 Trial: Once-Weekly Apraglutide Reduces Parenteral Support in Short Bowel Syndrome-Intestinal Failure
Joly et al. 2026 · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 163 people · cited by 0
6 results
People
Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial
Eliasson et al. 2022 · JPEN. Journal of parenteral and enteral nutrition · 8 people · cited by 40
10 results
People
Characterization of the Pharmacokinetic and Pharmacodynamic Profile of Apraglutide, a Glucagon-Like Peptide-2 Analog, in Healthy Volunteers
Bolognani et al. 2023 · The Journal of pharmacology and experimental therapeutics · cited by 7
7 results
People
Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long-Acting, Synthetic glucagon-like peptide-2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function
Greig et al. 2024 · Journal of clinical pharmacology · 16 people · cited by 5
3 results
People
Pharmacokinetics and Safety of Single-Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open-Label Trial
Greig et al. 2026 · Clinical pharmacology in drug development · 16 people · cited by 0
3 results

All 16 Apraglutide studies

Apraglutide clinical trials

ClinicalTrials.gov lists no trial of apraglutide. A trial under another name may exist.

Status and safety

Is apraglutide approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Status unknown

Status unknown.

WADA

Sport

Not recorded

Status unknown.

No. Not approved for any use. Its most advanced trial is in phase 3. The FDA and the other sources we use show no approval (as of 27 Oct 2026). Status unknown.

Laws and labels change, so check the regulator for the current status.

Apraglutide side effects and safety

PepBank has 21 safety results from studies of apraglutide. 20 of them come from studies in people.

Safety results from studies (21)

In adults with SBS-IF, apraglutide treatment caused mild to moderate excessive urination. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In people with short bowel syndrome, apraglutide was reported as well tolerated. (Clinical gastroenterology and hepatology, 2026)
In adults with short bowel syndrome receiving apraglutide, most reported adverse events were mild to moderate. (Clinical nutrition, 2024)
In adults with SBS, reduced GI stoma output occurred in 6 patients receiving apraglutide. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In the apraglutide liver-function trial, adverse events were mild or moderate. (Clinical pharmacology in drug development, 2026)
In the apraglutide kidney-function trial, adverse events were mild or moderate. (Journal of clinical pharmacology, 2024)
In adults with SBS-IF, reduced stoma output was a mild to moderate event related to apraglutide treatment. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In adults with SBS-IF, mild to moderate stoma complications occurred with apraglutide treatment. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In adults with SBS-IF, reduced thirst was a mild to moderate event related to apraglutide treatment. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In adults with SBS-IF, mild to moderate swelling occurred with apraglutide treatment. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In adults with SBS-IF, no serious adverse events were considered related to apraglutide. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In adults with SBS-IF, lower and higher apraglutide doses had similar safety profiles. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In adults with SBS, stoma complications occurred in 6 patients receiving apraglutide. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In adults with SBS, GI stoma complications occurred in 5 patients receiving apraglutide. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In adults with SBS, nausea occurred in 5 patients receiving apraglutide. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In adults with SBS, gas occurred in 4 patients receiving apraglutide. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In adults with SBS, abnormal GI stoma output occurred in 4 patients receiving apraglutide. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In adults with SBS, excessive urination occurred in 3 patients receiving apraglutide. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In adults with SBS, abdominal pain occurred in 3 patients receiving apraglutide. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In adults with SBS, one patient had serious abdominal pain related to apraglutide treatment. (JPEN. Journal of parenteral and enteral nutrition, 2022)
In piglets with SBS, apraglutide and saline groups were healthy on day 7. (JPEN. Journal of parenteral and enteral nutrition, 2019)

See every safety result on the Scientific page

Doses studied (13 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
5 or 10 mg once weekly	Human	human	Not reported	4 weeks	Randomized trial in people · n = 8	Eliasson 2022
5 mg once weekly	Human	human	Not reported	4 weeks	Randomized trial in people · n = 8	Eliasson 2022
1, 5, or 10 mg weekly	Human	human	subcutaneous	6 weekly administrations	Randomized trial in people	Bolognani 2023
5 mg weekly	Human	human	subcutaneous	6 weekly administrations	Randomized trial in people	Bolognani 2023
10 mg weekly	Human	human	subcutaneous	6 weekly administrations	Randomized trial in people	Bolognani 2023
5 mg	Human	human	subcutaneous	single dose	Trial in people without random groups · n = 16	Greig 2024
3.5 mg	Human	human	Not reported	single dose	Trial in people without random groups · n = 16	Greig 2026
5 mg once weekly	Human	human	subcutaneous	4 weeks	Trial in people without random groups · n = 8	Eliasson 2022
10 mg once weekly	Human	human	Not reported	4 weeks	Trial in people without random groups · n = 8	Eliasson 2022
5 mg/kg/dose twice weekly	Animal	pig	Not reported	Not reported	Study in live animals · n = 23	Pauline 2021
5 mg/kg on days 0 and 4	Animal	pig	subcutaneous	Not reported	Study in live animals · n = 18	Slim 2019
3 mg/kg three times per week	Animal	mouse	Not reported	3 weeks	Study in live animals	Martchenko 2020
5 mg/kg twice weekly	Animal	pig	Not reported	7 days	Study in live animals	Hinchliffe 2021

Questions and more

Ask a question about apraglutide

The answer links to every study it uses.

What does the evidence say about apraglutide?Is apraglutide tested in people?Compare with Teduglutide Compare with Glepaglutide

Sources

Database: PepBank data for apraglutide (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about apraglutide

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Apraglutide

Apraglutide at a glance

What is apraglutide?

Apraglutide structure and chemistry